Small Molecular Gemcitabine Prodrugs for Cancer Therapy
| Autor: | Yepeng Luan, Xuehong Chen, He Miao |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
media_common.quotation_subject Antineoplastic Agents Drug resistance Deoxycytidine Biochemistry 03 medical and health sciences 0302 clinical medicine Neoplasms Drug Discovery medicine Humans Prodrugs Nucleotide 030304 developmental biology media_common Pharmacology chemistry.chemical_classification 0303 health sciences Organic Chemistry Deoxycytidine kinase Prodrug Gemcitabine chemistry 030220 oncology & carcinogenesis Toxicity Cancer research Molecular Medicine Nucleoside medicine.drug |
| Zdroj: | Current Medicinal Chemistry. 27:5562-5582 |
| ISSN: | 0929-8673 |
| DOI: | 10.2174/0929867326666190816230650 |
| Popis: | Gemcitabine as a pyrimidine nucleoside analog anticancer drug has high efficacy for a broad spectrum of solid tumors. Gemcitabine is activated within tumor cells by sequential phosphorylation carried out by deoxycytidine kinase to mono-, di-, and triphosphate nucleotides with the last one as the active form. But the instability, drug resistance and toxicity severely limited its utilization in clinics. In the field of medicinal chemistry, prodrugs have proven to be a very effective means for elevating drug stability and decrease undesirable side effects including the nucleoside anticancer drug such as gemcitabine. Many works have been accomplished in design and synthesis of gemcitabine prodrugs, majority of which were summarized in this review. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|